Fri, 29 Jan 2021
Source: reuters.com
South Africa’s mid-stage trial of U.S.-based biotech company Novavax Inc’s COVID-19 vaccine has shown it to be 60% effective for non-HIV individuals, the principal investigator of the study said late on Thursday.
Shabir Madhi, a professor of vaccinology at the University of the Witwatersrand leading the clinical study for Novavax COVID-19 vaccine in South Africa, said the results were good and showed the vaccine is highly effective towards immunization against the coronavirus.
“The results are far superior than any other vaccine against the new variant,” Madhi said.
Source: reuters.com
Related Articles:
- They're giving us irrelevant explanations after forcing COVID-19 vaccines on us - Kwesi Pratt fumes
- EU Member States contributed €55 million for vaccine manufacturing in Ghana - Report
- Our vaccination efforts reduced adverse effects of COVID-19 – Disease Control Officer
- COVID-19: 31 cases recorded in the past week - GHS
- Ghana records 21 new COVID-19 cases in Greater Accra, Bono Regions
- Read all related articles